The 9th CIIE Transforms Medical Innovation Incubation Zones into Global Accelerators

The 9th China International Import Expo (CIIE) has once again captured global attention, serving not merely as a traditional trade exhibition window but increasingly as a powerful innovation accelerator. Within the medical innovation incubation zone, multinational corporations and domestic enterprises are connecting global dual-circulation strategies to bring cutting-edge healthcare solutions to the market.

Major global pharmaceutical and healthcare giants, such as Bayer, Novartis, AstraZeneca, and homegrown innovators like InlyMedia, have made significant impacts at this year’s expo. Bayer marked its continuous participation by showcasing nearly 30 premier product launches and first-time exhibitions. Meanwhile, Novartis presented its latest research and development footprint in China, highlighting advanced therapeutic breakthroughs.

AstraZeneca utilized the CIIE platform to announce multiple strategic investments and operational expansions within China, aimed at accelerating the localization of global medical innovations. In parallel, InlyMedia introduced six major artificial intelligence-enabled healthcare scenario solutions, demonstrating how technology can reconstruct the comprehensive health industry ecosystem.

By bridging international resources with China’s vast domestic market, the medical innovation zone at the 9th CIIE continues to facilitate high-level openness and collaboration. Industry leaders agree that the event plays a crucial role in driving medical advancements and fostering sustainable partnerships that benefit patients worldwide.

Sources: Shanghai Enterprise Going Global Comprehensive Service Platform

Aggregated summary. Original: 上海市企业走出去综合服务平台